---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-003441"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2024-01-23T23:59:59+00:00"
generated_at: "2026-06-06T20:12:54.686326+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Indaptus amends bylaws to adopt universal proxy rules and exclusive federal forum

## Summary
- Board adopted amended bylaws effective Jan 22, 2024, addressing universal proxy rules (Rule 14a-19 compliance).
- Enhanced disclosure requirements for stockholder director nominations and business proposals.
- Prohibits stockholder from submitting more director nominees than seats for election.
- Requires proxy cards other than white for stockholders soliciting proxies.
- Establishes federal district courts as exclusive forum for Securities Act claims.

## SEC filing metadata
- accession: 0001493152-24-003441
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2024-01-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315224003441/0001493152-24-003441-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315224003441/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-003441
- JSON: https://secwatch.observer/filing/0001493152-24-003441.json
- Plain text: https://secwatch.observer/filing/0001493152-24-003441.txt

## Key facts
- Governance Changes
  Indaptus Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, streamline stockholder nomination procedures, add exclusive forum provision, and make technical changes (effective 2024-01-22).
  - Change: bylaw amendment
  - Effective: 2024-01-22
  source text: On January 22, 2024, the Board of Directors (the “ Board ”) of Indaptus Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315224003441/0001493152-24-003441-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.